Trial Profile
Effect of PPAR-Delta Agonist on Lipoprotein Kinetics in Metabolic Syndrome.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Aug 2023
Price :
$35
*
At a glance
- Drugs GW 501516 (Primary)
- Indications Metabolic syndrome
- Focus Pharmacodynamics
- 18 Jun 2009 Results were reported at the 15th International Symposium on Atherosclerosis.
- 14 Jun 2009 Results were presented at the 15th International Symposium on Atherosclerosis (ISA) in Boston, MA.
- 14 Feb 2009 New trial record